Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

Researchers trace the origin of blood cancer to early childhood, decades before...

Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK

Researchers trace the origin of blood cancer to early childhood, decades before diagnosis ( Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK )

Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

$Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by measuring circulating tumour DNA ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )$

ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr...

$ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma ( Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith )$

Survival analysis of newly diagnosed transplant-eligible multiple myeloma...

Dr Francesca Gay - University of Torino, Torino, Italy

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial ( Dr Francesca Gay - University of Torino, Torino, Italy )

Circulating tumour cell dynamics as a predictor for treatment response and...

Prof Wolfgang Janni - Ulm University, Ulm, Germany

Circulating tumour cell dynamics as a predictor for treatment response and prognosis in metastatic breast cancer patients ( Prof Wolfgang Janni - Ulm University, Ulm, Germany )

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with...

Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ( Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy )

Latest data for managing ALK NSCLC patients

Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea

Latest data for managing ALK NSCLC patients ( Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea )

ASCENT: A phase II trial of induction, consolidation and maintenance in...

Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM ( Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA )

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk...

Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve...

Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings ( Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer